Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

CCRAS launches ‘SMART 2.0’ for ayurveda teaching professionals

Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics

The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares

FDA grants priority review to Merck’s new biologics license application for V116

V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults

Zydus inks licensing agreement with Daewoong Pharmaceutical for leuprolide injectable in the US

The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome

Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH

Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer

In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)

ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy